Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications
Biomind Labs Inc. ; class='js-l-obf link link--blue'
Stay updated with breaking news from Biomind Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biomind Labs Inc. ; class='js-l-obf link link--blue'
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal...
Biomind Labs and Queen’s University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System - read this article along with other careers information, tips and advice on BioSpace
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression - read this article along with other careers information, tips and advice on BioSpace
Biomind Labs Inc. ("Biomind Labs" or the "Company") (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from